1
|
Mueller LG, Chao A, Alwedi E, Natrajan M, Fleming FF. Oxazole Synthesis by Sequential Asmic-Ester Condensations and Sulfanyl-Lithium Exchange-Trapping. Org Lett 2021; 23:1500-1503. [PMID: 33533625 DOI: 10.1021/acs.orglett.1c00288] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Oxazoles are rapidly assembled through a sequential deprotonation-condensation of Asmic, anisylsulfanylmethylisocyanide, with esters followed by sulfanyl-lithium exchange-trapping. Deprotonating Asmic affords a metalated isocyanide that efficiently traps esters to afford oxazoles bearing a versatile C-4 anisylsulfanyl substituent. Interchange of the anisylsulfanyl substituent is readily achieved through a first-in-class sulfur-lithium exchange-electrophilic trapping sequence whose versatility is illustrated in the three-step synthesis of the bioactive natural product streptochlorin.
Collapse
Affiliation(s)
- Louis G Mueller
- Department of Chemistry, Drexel University, 32 South 32nd Street Philadelphia, Pennsylvania 19104, United States
| | - Allen Chao
- Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, United States
| | - Embarek Alwedi
- Merck Inc., 90 East Scott Avenue, Rahway, New Jersey 07065, United States
| | - Maanasa Natrajan
- Department of Chemistry, Drexel University, 32 South 32nd Street Philadelphia, Pennsylvania 19104, United States
| | - Fraser F Fleming
- Department of Chemistry, Drexel University, 32 South 32nd Street Philadelphia, Pennsylvania 19104, United States
| |
Collapse
|
2
|
Keith JM, Jones W, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm M, Chang L, Rizzolio M, Rynberg R, Chaplan S, Guy Breitenbucher J. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2020; 30:127463. [PMID: 32784090 DOI: 10.1016/j.bmcl.2020.127463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 07/27/2020] [Accepted: 08/02/2020] [Indexed: 12/18/2022]
Abstract
A series of mechanism-based heteroaryl urea fatty acid amide hydrolase (FAAH) inhibitors with fused bicyclic diamine cores is described. In contrast to compounds built around a piperazine core, most of the fused bicyclic diamine bearing analogs prepared exhibited greater potency against rFAAH than the human enzyme. Several compounds equipotent against both species were identified and profiled in vivo.
Collapse
Affiliation(s)
- John M Keith
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.
| | - William Jones
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Joan M Pierce
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Mark Seierstad
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - James A Palmer
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Michael Webb
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Mark Karbarz
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Brian P Scott
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Sandy J Wilson
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Lin Luo
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Michelle Wennerholm
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Leon Chang
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Michele Rizzolio
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Raymond Rynberg
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - Sandra Chaplan
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | - J Guy Breitenbucher
- Janssen Pharmaceutical Companies of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| |
Collapse
|
3
|
Boger DL. The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface. J Org Chem 2017; 82:11961-11980. [PMID: 28945374 PMCID: PMC5712263 DOI: 10.1021/acs.joc.7b02088] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Indexed: 01/24/2023]
Abstract
A Perspective of work in our laboratory on the examination of biologically active compounds, especially natural products, is presented. In the context of individual programs and along with a summary of our work, selected cases are presented that illustrate the impact single atom changes can have on the biological properties of the compounds. The examples were chosen to highlight single heavy atom changes that improve activity, rather than those that involve informative alterations that reduce or abolish activity. The examples were also chosen to illustrate that the impact of such single-atom changes can originate from steric, electronic, conformational, or H-bonding effects, from changes in functional reactivity, from fundamental intermolecular interactions with a biological target, from introduction of a new or altered functionalization site, or from features as simple as improvements in stability or physical properties. Nearly all the examples highlighted represent not only unusual instances of productive deep-seated natural product modifications and were introduced through total synthesis but are also remarkable in that they are derived from only a single heavy atom change in the structure.
Collapse
Affiliation(s)
- Dale L. Boger
- Department of Chemistry and
The Skaggs Research Institute, The Scripps
Research Institute, 10550
North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
4
|
Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson S, Luo L, Wennerholm ML, Chang L, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett 2015; 6:1204-8. [PMID: 26713105 PMCID: PMC4677372 DOI: 10.1021/acsmedchemlett.5b00353] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Accepted: 11/02/2015] [Indexed: 01/20/2023] Open
Abstract
The pre-clinical characterization of the aryl piperazinyl urea inhibitor of fatty acid amide hydrolase (FAAH) JNJ-42165279 is described. JNJ-42165279 covalently inactivates the FAAH enzyme, but is highly selective with regard to other enzymes, ion channels, transporters, and receptors. JNJ-42165279 exhibited excellent ADME and pharmacodynamic properties as evidenced by its ability to block FAAH in the brain and periphery of rats and thereby cause an elevation of the concentrations of anandamide (AEA), oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA). The compound was also efficacious in the spinal nerve ligation (SNL) model of neuropathic pain. The combination of good physical, ADME, and PD properties of JNJ-42165279 supported it entering the clinical portfolio.
Collapse
Affiliation(s)
- John M. Keith
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - William M. Jones
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Mark Tichenor
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Jing Liu
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Mark Seierstad
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - James A. Palmer
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Michael Webb
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Mark Karbarz
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Brian P. Scott
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Sandy
J. Wilson
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Lin Luo
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Michelle L. Wennerholm
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Leon Chang
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Michele Rizzolio
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Raymond Rynberg
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Sandra R. Chaplan
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - J. Guy Breitenbucher
- Janssen Pharmaceutical Companies
of Johnson & Johnson, L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| |
Collapse
|
5
|
Otrubova K, Srinivasan V, Boger DL. Discovery libraries targeting the major enzyme classes: the serine hydrolases. Bioorg Med Chem Lett 2014; 24:3807-13. [PMID: 25037918 DOI: 10.1016/j.bmcl.2014.06.063] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2014] [Revised: 06/19/2014] [Accepted: 06/20/2014] [Indexed: 11/19/2022]
Abstract
Two libraries of modestly reactive ureas containing either electron-deficient acyl anilines or acyl pyrazoles were prepared and are reported as screening libraries for candidate serine hydrolase inhibitors. Within each library is a small but powerful subset of compounds that serve as a chemotype fragment screening library capable of subsequent structural diversification. Elaboration of the pyrazole-based ureas provided remarkably potent irreversible inhibitors of fatty acid amide hydrolase (FAAH, apparent Ki=100-200 pM) complementary to those previously disclosed enlisting electron-deficient aniline-based ureas.
Collapse
Affiliation(s)
- Katerina Otrubova
- Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla CA 92037, United States
| | - Venkat Srinivasan
- Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla CA 92037, United States
| | - Dale L Boger
- Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla CA 92037, United States.
| |
Collapse
|